AI-Supported Mammography Screen Reading Seems Promising
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 7, 2023 -- Cancer detection is similar for artificial intelligence (AI)-supported mammography screen reading compared with standard double reading, according to a study published online Aug. 1 in The Lancet Oncology.
Kristina Lång, Ph.D., from Lund University in Sweden, and colleagues conducted a randomized, controlled, population-based trial involving women aged 40 to 80 years who were eligible for mammography screening at four sites in Sweden. Participants were randomly assigned to AI-supported screening or standard double reading without AI. The AI system provided an examination-based malignancy risk score, which was used to triage screening examinations to single-reading or double-reading risk scores. This study reported the prespecified clinical safety analysis for 80,033 women randomly assigned to AI-supported screening (40,003 women) or double reading without AI (40,030 women).
The researchers found that cancer detection rates were 6.1 and 5.1 per 1,000 screened participants in the intervention and control groups, respectively; the detection rate in the intervention group was above the lowest acceptable limit for safety. Recall rates were 2.2 and 2.0 percent in the intervention and control groups, respectively. In both groups, the false-positive rate was 1.5 percent. The positive predictive value of recall was 28.3 and 24.8 percent in the intervention and control groups, respectively. In the intervention group, 75 and 25 percent of cancers detected were invasive and in situ, respectively, compared with 81 and 19 percent, respectively, in the control group. Using AI, the screen-reading workload was reduced by 44.3 percent.
"The greatest potential of AI right now is that it could allow radiologists to be less burdened by the excessive amount of reading," Lång said in a statement.
One author disclosed ties to the pharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Pandemic Had Temporary Negative Effect on Breast Cancer Screening
THURSDAY, May 30, 2024 -- The COVID-19 pandemic had a transient negative effect on breast cancer screening overall and a prolonged negative effect on follow-up screening...
Patient Characteristics Linked to Performance of AI Algorithm for DBT
THURSDAY, May 30, 2024 -- For analyzing negative screening digital breast tomosynthesis (DBT) examinations, patient characteristics influence the case and risk scores of an...
Chemo + Breast Cancer Combo Accelerates Functional Decline in Seniors
WEDNESDAY, May 29, 2024 -- The combination of breast cancer and chemotherapy contributes to accelerated functional decline in older women with early-stage breast cancer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.